On the Radar: Five high-value biotech stocks

Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value

4D Molecular Therapeutics and Roche Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development

Pioneer in gene therapy vector discovery partners with leading biopharmaceutical company to create and develop products for genetic diseases April 27, 2015 07:15 AM Eastern Daylight Time SAN...

Roche's $100M Alzheimer's study could shift the balance in R&D

Despite all the excitement over Biogen's recent Phase I success in Alzheimer's, the question of whether attacking protein buildups in the brain can in fact treat the disease remains the subject of intense debate in the neurology world. And Roche, at work on a $100 million trial, is out to find out once and for all.

Synta Announces Chen Schor Named President, Chief Executive Officer and Director

LEXINGTON, Mass.--Synta Pharmaceuticals Corp. (SNTA) announced today that Chen Schor, Executive Vice President, Chief Operating Officer, has been named President, Chief Executive Officer and a...

Synta CEO bolts after less than a year, leaving a biotech on the mend

Synta Pharmaceuticals CEO Anne Whitaker is stepping down after just 9 months at the helm, heading back to Big Pharma as the company trims down and rallies around its cancer candidate.

BioMarin Completes Rolling NDA Submission to FDA for Drisapersen for Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

SAN RAFAEL, Calif., April 27, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (BMRN) today announced completion of the rolling submission of a New Drug Application (NDA) to the United States...

Adaptimmune sets terms for $150M IPO; BioMarin completes app for DMD drug drisapersen;

@FierceBiotech: Biogen partner Sobi and its Boston-based CEO field a takeover bid. News | Follow @FierceBiotech @JohnCFierce: No, $BLUE is not $CLDN. Not hard to separate these companies'...

UPDATED: FDA review challenges Amgen on a questionable T-Vec study

An internal FDA review of Amgen's study of its cancer-killing virus talimogene laherparepvec (T-Vec), released Monday morning, raises red flags for this drug, presenting some thorny questions for the company's regulatory team to answer.

Celgene to Acquire Quanticel Pharmaceuticals

Celgene Committed to Expanding Sustainable Pipeline of Life-Enhancing Medical Innovation to Benefit Cancer Patients Celgene Expects Acquisition to be Neutral to Adjusted Diluted Earnings in 2015...

Celgene bags a build-to-buy biotech in $485M cancer deal

A few years after teaming up with Versant Ventures to get Stanford spinout Quanticel Pharmaceuticals off the ground, Celgene is buying the cancer-focused biotech for up to $485 million.